期刊文献+

前列腺癌标志物的新进展

Progresses about Biomarkers for Prostate Cancer
下载PDF
导出
摘要 随着基因组学和蛋白质组学的进步,新的肿瘤标志物层出不穷,新发现的前列腺癌标志物有人激肽相关肽酶2、基质金属蛋白酶、前列腺特异性膜抗原、前列腺癌抗原3、早期前列腺抗原、胰岛素样生长因子与结合蛋白、尿激酶纤溶酶原激活物及其受体、α甲基乙酰辅酶A限速酶、转化生长因子β1、前列腺分泌蛋白94、E-钙黏素、白细胞介素配体和受体和肿瘤抗原的自身抗体。本文对这些新标志物予以综述。 With the development of genomies and proteomies, new tumor markers are increasing. The new found markers for prostate eaneer includes many kinds, such as kallikrein2, matrix metalloproteinase, prostate member specific antigen, prostate cancer antigen 3, early prostate cancer antigen, insulin-like growth factor, urokinase plasminogen aetivator, a-methyaeyl-CoA rasemase, transforming growth factor-β1 , prostate secretory protein 94, e-eadherin ,interlukine-6 and its soluble receptor, autoantibody of tumor antigen and so on. This article reviews the related markers of prostate cancer.
出处 《医学综述》 2009年第16期2437-2440,共4页 Medical Recapitulate
关键词 标志物 前列腺癌 早期诊断 特异性 敏感性 Biomarker Prostate cancer Early diagnosis Specificity Sensitivity
  • 相关文献

参考文献30

  • 1Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer[J]. Clin Chem,2004,50(6) :1017-1025.
  • 2吴健民.PSA检测前列腺癌临床应用的建议[J].诊断学理论与实践,2005,4(3):181-184. 被引量:4
  • 3aStamey TA. Preoperation serum prostate-specific antigen (PSA) below 10 μg/L predicats neither the presence of prostate cancer nor the rate of postoperation PSA failure[ J]. Clin Chem ,2001,47 (4) :631-634.
  • 4Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prosrate cancer among men with a prostate-specific antigen level ≤4 μg/L[ J]. N Engl ned,2004,350(22) :2239-2246.
  • 5Reeker F, Kwiatkowski MK, Pironen T, et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostatespecific antigen [ J ]. Urology, 2000,55 ( 3 ) :481-485.
  • 6潘兵,朱惠芳.基质金属蛋白酶与前列腺癌的相关探讨[J].中国肿瘤临床,2005,32(10):596-598. 被引量:3
  • 7叶传忠,张永康.前列腺癌肿瘤标记物研究进展[J].中国肿瘤临床,2000,27(12):945-947. 被引量:3
  • 8van Gils MP,Hessels D,van Hooij O,et al. The time-resolved fluorescence based PCA3 test on urinary sediments after digital rectal examination [ J ]. Clin Cancer Res,2007,13 (3) :939-943.
  • 9Marks KS, Fradet Y, Deras IL, et al. PCA3 molecule urine assay for prostate cancer in men undergoing repeat biopsy [ J]. Urology, 2007,69 ( 3 ) :532-535.
  • 10Paul B, Dhir R, Landsittel D, et al.Detection of prostate cancer with a blood-based assay for early prostate cancer antigen [ J ]. Cancer Res ,2005 ,65 ( 10 ) :4097 -4100.

二级参考文献40

  • 1[1]Babaian R. NCCN Prostate Cancer Early Detection.Clinic Practice Guidelines in Oncology-V. 1 [DB]. National Comprehensive Cancer Network, 2004.
  • 2[2]Fleisher M, Dnistrian AM, Sturgeon CM, et al. Practice guidelines and recommendations for use tumor markers in the clinic[M]. Washington DC:AACC Press, 2002.
  • 3[3]Semjonow A, Albrecht W, Bialk P, et al. Tumor markers in prostate cancer:EGTM recommendations[J]. Anticancer Res, 1999,19(4A):2799-2801.
  • 4[4]Duffy MJ, McGing P, McSweeney J. Guidelines for the use of tumor markers, produced on behalf of the scientific committee of the ACBI[M]. 2nd ed. 2000.
  • 5[5]Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges[J]. JAMA, 1993,270(7):860-864.
  • 6[6]Paul R, Breul J, Hartung R. Prostate-specific antigen density and age-specific prostate-specific antigen values:the solution of prostate cancer screening [J]? Eur Urol,1995,27(4):286-291.
  • 7[7]Schmid HP. Prostate specific antigen doubling time in diagnosis and follow-up of patients with prostate cancer [J]. Tumour Marker Update, 1996,8:71-77.
  • 8[8]D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy[J]. N Engl J Med, 2004,351(2):125-135.
  • 9[9]Bangma CH, Kranse R, Blijenberg BG, et al. The value of screening tests in the detection of prostate cancer. Part Ⅱ: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density[J]. Urology, 1995,46(6):779-784.
  • 10[10]Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening[J]. JAMA,1995,274(15):1214-1220.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部